The Peptide Authority

Research Hub

Retatrutide Research

Retatrutide is an investigational agonist of the GIP, GLP-1, and glucagon receptors. This research hub organizes human clinical trials, systematic reviews, meta-analyses, and translational research indexed in The Peptide Authority library. Every record links to its original PubMed or DOI source for independent verification.

Retatrutide remains under clinical investigation. This page summarizes published research and does not provide medical advice, prescribing guidance, or treatment recommendations.

Evidence Snapshot

24Publicly indexed retatrutide records
2022–2026Publication year range
6Featured primary clinical trials
24 PubMed · 24 DOIVerified source links

Research Areas

Obesity and weight-management researchType 2 diabetes and glycaemic outcomesLiver and metabolic-disease researchBody-composition researchSystematic reviews and meta-analysesTranslational development

Featured

Featured Clinical Trials

Six primary retatrutide clinical-trial records selected by the editorial team. Each card links to its full indexed record and original source.

RCT·Lancet (London, England)·2026·LMC Diabetes and Endocrinology, Brampton, ON, Canada.

Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial

Bajaj, HS., Welch, M., Shah, P. et al.·PMID 4225057510.1016/S0140-6736(26)00967-0

Retatrutide is a GIP, GLP-1, and glucagon triple hormone receptor agonist, under clinical development for type 2 diabetes, obesity, and related complications. We aimed to assess the efficacy and safety of retatrutide as a monotherapy in people with type 2 diabetes that is inadequately controlled by diet and exercise alone. In this 40-week, phase 3, randomised, double-blind, pla…

Key Finding

Between April 10, 2024, and April 21, 2025, 930 participants were screened and 537 (296 [55%] female and 241 [45%] male) were randomly assigned: 134 to retatrutide 4 mg, 133 to retatrutide 9 mg, 136 to retatrutide 12 mg, and 134 to placebo.

RCT·The New England journal of medicine·2023·From the Departments of Medicine (Endocrinology and Metabolism) and Pediatrics (Pediatric Endocrinology), Yale University School of Medicine, New Have

Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial

Jastreboff, AM., Kaplan, LM., Frías, JP. et al.·PMID 3736631510.1056/NEJMoa2301972

Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose-response relationships with respect to side effects, safety, and efficacy for the treatment of obesity are not known. We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass i…

Key Finding

We enrolled 338 adults, 51.8% of whom were men.

RCT·Lancet (London, England)·2023·Velocity Clinical Research at Medical City, Dallas, TX, USA.

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA

Rosenstock, J., Frias, J., Jastreboff, AM. et al.·PMID 3738528010.1016/S0140-6736(23)01053-X

According to current consensus guidelines for type 2 diabetes management, bodyweight management is as important as attaining glycaemic targets. Retatrutide, a single peptide with agonist activity at the glucose-dependent insulinotropic polypeptide (GIP), GLP-1, and glucagon receptors, showed clinically meaningful glucose-lowering and bodyweight-lowering efficacy in a phase 1 st…

Key Finding

275 participants were included in the efficacy analyses (one each in the retatrutide 0·5 mg group, 4 mg escalation group, and 8 mg slow escalation group, and three in the 12 mg escalation group were inadvertently enrolled).

RCT·Nature medicine·2024·Stravitz-Sanyal Institute for Liver Disease and Metabolic Health and Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth Uni

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial

Sanyal, AJ., Kaplan, LM., Frias, JP. et al.·PMID 3885852310.1038/s41591-024-03018-2

Retatrutide is a novel triple agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and glucagon receptors. A 48-week phase 2 obesity study demonstrated weight reductions of 22.8% and 24.2% with retatrutide 8 and 12 mg, respectively. The primary objective of this substudy was to assess mean relative change from baseline in liver fat (LF) at 24 wee…

Key Finding

LF reductions were significantly related to changes in body weight, abdominal fat and metabolic measures associated with improved insulin sensitivity and lipid metabolism.

RCT·The lancet. Diabetes & endocrinology·2025·Eli Lilly and Company, Indianapolis, Indiana.

Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial

Coskun, T., Wu, Q., Schloot, NC. et al.·PMID 4060956610.1016/S2213-8587(25)00092-0

Retatrutide, a glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptor agonist, has demonstrated robust glucose and bodyweight reductions in participants with type 2 diabetes. This substudy assessed percent change from baseline to week 36 in total body fat mass versus placebo and dulaglutide. This phase 2, double-blind, parallel-group, place…

Key Finding

Between May 13, 2021 and June 13, 2022, 534 participants were screened for inclusion into the main study.

RCT·Lancet (London, England)·2022·Eli Lilly and Company, Indianapolis, IN, USA.

LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial

Urva, S., Coskun, T., Loh, MT. et al.·PMID 3635404010.1016/S0140-6736(22)02033-5

Treating hyperglycaemia and obesity in individuals with type 2 diabetes using multi-receptor agonists can improve short-term and long-term outcomes. LY3437943 is a single peptide with agonist activity for glucagon, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide 1 (GLP-1) receptors that is currently in development for the treatment of type 2 diabet…

Key Finding

Between Dec 18, 2019, and Dec 28, 2020, 210 people were screened, of whom 72 were enrolled, received at least one dose of study drug, and were included in safety analyses.

Library

Additional Human Research and Reviews

All remaining publicly indexed retatrutide records from the library, sorted by publication year. Includes reviews, meta-analyses, and human-subject studies.

Early Development

Translational Development

The following record contains translational and early-development research on retatrutide, including preclinical context and early phase human data. It is listed separately from the primary human clinical trials above.

Translational and early-development research — not a primary clinical outcome study
Animal Study·Cell metabolism·2022·Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept

Coskun, T., Urva, S., Roell, WC. et al.·PMID 3598534010.1016/j.cmet.2022.07.013

With an increasing prevalence of obesity, there is a need for new therapies to improve body weight management and metabolic health. Multireceptor agonists in development may provide approaches to fulfill this unmet medical need. LY3437943 is a novel triple agonist peptide at the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon…

Key Finding

Its pharmacokinetic profile supported once-weekly dosing, and a reduction in body weight persisted up to day 43 after a single dose.

Source and Editorial Standards

Study titles, authors, journals, publication years, PMIDs, DOIs, institutional affiliations, and source links are drawn from the existing indexed records. The Peptide Authority did not conduct or publish these studies. Inclusion does not imply endorsement by the original authors, institutions, journals, PubMed, or publishers.

Evidence Briefing

The Peptide Evidence Brief

Twice each month, receive the most important newly indexed studies, clinical trial updates, evidence summaries, and research developments, selected exclusively from trusted peer-reviewed journals.

Concise summaries with direct links to original publications. Quality over quantity. No promotional content.

Peer-reviewed sources onlyPublished twice monthlyNo promotional content

No spam. Unsubscribe at any time. We never share your data.